James Chih-Hsin Yang et al. explored the efficacy and safety of DZD9008 in NSCLC patients with EGFR ex20ins mutation, and the results showed that DZD9008 has good safety and antitumor efficacy in EGFR ex20ins NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.